Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.48 |
| ▸ | GRM3 | Q14832 | 5/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695863 | 0.76 | GRM2 (0.47) | GRM2GRM3GRM8GRM6SLC1A2 | |
| SCHEMBL6696167 | 0.72 | GRM2 (0.58) | GRM2GRM3GRM8GRM6SLC1A2 | |
| SCHEMBL6692372 | 0.72 | GRM8 (0.48) | GRM2GRM3GRM8GRM6SLC1A2 | |
| SCHEMBL6695868 | 0.72 | GRM8 (0.48) | GRM2GRM3GRM8GRM6SLC1A2 | |
| SCHEMBL6693393 | 0.71 | GRM2 (0.50) | GRM2GRM3GRM8GRM6SLC1A2 | |
| SCHEMBL6702212 | 0.71 | GRM2 (0.50) | GRM2GRM3GRM8GRM6SLC1A2 | |
| SCHEMBL6693397 | 0.71 | GRM2 (0.50) | GRM2GRM3GRM8GRM6SLC1A2 | |
| Hydrochloric Acid SCHEMBL5841686 | 0.70 | GRM2 (0.45) | GRM2GRM3GRM8GRM6SLC1A2 | |
| Hydrochloric Acid SCHEMBL6697712 | 0.69 | GRM2 (0.54) | GRM2GRM3GRM8GRM6SLC1A2 | |
| SCHEMBL5840776 | 0.69 | SLC1A2 (0.48) | GRM2GRM3GRM8GRM6SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176459-A1 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY | 2004-09-09 | — | — | US | claimed |
| US-20040176459-A1 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176459-A1 | Prodrugs of excitatory amino acids | SLC1A2, SLC1A1, SLC1A3 | GRM2 22/4885GRM3 25/4885GRM8 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.